A RANDOMIZED, PHASE 3, OPEN LABEL STUDY EVALUATING SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
- Registry ID
- EFC15951
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- SANOFI-AVENTIS CANADA INC
- Start date
- 2023-12-13
- Last update
- 2022-06-10
Conditions
- MYELOMA
- MULTIPLE MYELOMA
- RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Related clinical trials
- A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
- A PHASE 3 RANDOMIZED STUDY COMPARING JNJ-79635322 AND AN ANTI-BCMAXCD3 BISPECIFIC ANTIBODY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 3 PRIOR LINES OF THERAPY INCLUDING A PI, AN IMID, AND AN ANTI-CD38 ANTIBODY
- A PHASE III OPEN-LABEL, RANDOMISED, MULTICENTRE STUDY COMPARING AZD0120, A DUAL-TARGETING AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY DIRECTED AGAINST BCMA AND CD19, VERSUS STANDARD REGIMENS IN PARTICIP WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (DURGA-4)
- PHASE I DOSE ESCALATION STUDY OF LIPOSOMAL CURCUMIN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
- A PHASE 1B/2A, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED
DOSE AND SCHEDULE, AND EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF
MEZIGDOMIDE IN COMBINATION WITH ELRANATAMAB IN PARTICIPANTS WITH RELAPSED
AND/OR REFRACTORY MULTIPLE MYELOMA
- A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL, GROUP-SEQUENTIAL,
PHASE 3 STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF
INTRAVENOUS GAMMAGARD LIQUID (IMMUNE GLOBULIN INFUSION, 10%) FOR
PRIMARY INFECTION PROPHYLAXIS COMPARED WITH SECONDARY INFECTION
PROPHYLAXIS IN ADULT SUBJECTS WITH MULTIPLE MYELOMA RECEIVING B-CELL
MATURATION ANTIGEN×CD3¿DIRECTED BISPECIFIC ANTIBODY THERAPY
View on source registry